Dajiang Liu

I am excited to share our new work that generates a single cell eQTL atlas for immune cell types. The work integrates bulk eQTLs with sc-eQTLs, which boosts the power for identifying sc-eQTLs for up to 4 folds. As such, we have the power equivalent to sc-RNASeq of 4K individuals.

NIH will only accept six applications per PI per calendar year. drugmonkey.wordpress.com/2025/07/17/nih… via @drugmonkeyblog

News: NIH to crack down on excessive publisher fees for publicly funded research bit.ly/4nCdIbl

Huge thanks to everyone who supported this work- especially the brilliant and twitterless (X-less?) Dr. Matthew Coates, @dajiangliu81, as well as @PennStHershey, @PennStGastroHep, @OslerResidency, and @OslerPSP. Grateful for your guidance and collaboration throughout 🙏

A nice article covering our work! Thanks @HealioRheum for the coverage!

2⃣The biggest problem in deriving sc-eQTLs is that scRNAseq is expensive and thus such datasets small. By combining bulk-tissue eQTLs with sc-eQTLs, a new method increases sc-eQTL detection by almost 6x and statistical power by 3.5x❗️ 7/9

I am thrilled to share one of the most important projects from my PhD! We developed the method JOBS (JOint model of Bk-eQTLs as a weighted sum of Sc-eQTLs) and applied it to blood bulk (eQTLGen) and sc-eQTL (OneK1K). 1/3

a single-author paper by @MengjieChen6. Kudos for a busy PI.

Is it serious? Almost daily airplane accident news now. msn.com/en-us/travel/n…

I really thought this was a joke or troll when I first saw it. WOW!

I am only slightly better and can use word and endnote really well, as well.

At this point of his career, only winning majors matters. To do so, @DjokerNole has to beat Alcaraz (already done), Zverev, and likely Sinner, the top 3 players of last year. Kind of unthinkable. But who knows.

I think part of it is that there are so many journals now and it has become a lot easier to publish somewhere. Many applicants, even before grad school, have papers, and some are first author papers. That is very rare in the days when I was an applicant.

I’m thrilled to share that a piece of my Ph.D work @BioinformPSU on predicting disease progression risk from preclinical states is now published in @NatureComms . I’m deeply grateful for all the guidance and encouragement from my wonderful advisor @dajiangliu81

Excited to share a part of my PhD thesis! We developed a novel method to predict the risk of progression from pre-clinical to clinical disease for SLE and RA. So thankful to my co-first author @ChenWang_PSU and mentors @dajiangliu81 and Dr. Bibo Jiang

Check out our latest work on Genetic Progression Score (GPS) to predict the progression of autoimmune diseases from preclinical stages. Work led by @ChenWang_PSU and @MarkusHavell.